title: Use of recombinant human follicle-stimulating hormone for in vitro fertilization-embryo transfer after severe systemic immunoglobulin E-mediated reaction to urofollitropin.
abstract: OBJECTIVE
  To report the successful use of recombinant human FSH in a patient with a history of a severe systemic immunoglobulin E (IgE)-mediated reaction to urofollitropin.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  A 38-year-old infertility patient who had experienced a whole-body rash with hives, tachycardia, fever, and other symptoms after urofollitropin administration, with confirmation of IgE-mediated sensitivity to urofollitropin by intradermal skin testing.
  
  
  METHODS
  In vitro fertilization-ET after the use of recombinant human FSH to stimulate ovarian follicular development.
  
  
  RESULTS
  Establishment of a clinical pregnancy.
  
  
  CONCLUSIONS
  Our case provides evidence for the involvement of nongonadotropin proteins as the direct cause of some adverse reactions from conventional urine-derived human FSH preparations.
authors: Department of Obstetrics-Gynecology, University of Rochester, New York 14642, USA.
authors: W R
authors: WR
authors: Phipps
authors: D
authors: D
authors: Holden
authors: R K
authors: RK
authors: Sheehan
mesh_terms: D000328:Adult; D004342:Drug Hypersensitivity / Q000276:immunology*; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000276:immunology* / Q000627:therapeutic use* / Q000652:urine; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology*; D011247:Pregnancy; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D007073:Immunoglobulin E; D005640:Follicle Stimulating Hormone